ILB-2109 not checked

Innolake Biopharm

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.”In the company’s words, NCT05278546 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor
Main trialPhase 1
“This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.”In the company’s words, NCT05278546 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2439 drugs for Advanced Solid Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Dec 2024 A Study of ILB2109 in Patients With Advanced Solid Malignancies
Phase 1/2Unknown 25 Jan 2026 A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ILB-2109

Following is part of Solo: you see every change to ILB-2109 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in